Scientists Uncover Role of Alzheimer’s-Linked APOE Gene in Glaucoma Protection and Identify Promising Treatment Strategy to Prevent Vision Loss

Scientists have demonstrated that the APOE4 gene variant, which increases risk for Alzheimer’s but decreases risk of glaucoma in humans, blocks a disease cascade that leads to the destruction of retinal ganglion cells in glaucoma. Additionally, they showed in mouse models that the death of retinal ganglion cells – the cause of vision loss in glaucoma – can be prevented by using medications to inhibit a molecule called Galectin-3, which is regulated by the APOE gene. These findings taken together emphasize the critical role of APOE in glaucoma and suggest that Galectin-3 inhibitors hold promise as a glaucoma treatment, according to the authors.

WVU researcher says gene discovery may lead to new tests, treatments for Alzheimer’s in women

Women make up two-thirds of Americans who have Alzheimer’s disease, yet scientists have yet to determine what makes them so susceptible to the condition. Bernard Schreurs, a researcher with the West Virginia University School of Medicine and Rockefeller Neuroscience Institute, directs the West Virginia Alzheimer’s…